As of Mar 27
| -0.13 / -3.36%|
The 8 analysts offering 12-month price forecasts for AcelRx Pharmaceuticals Inc have a median target of 7.00, with a high estimate of 15.00 and a low estimate of 4.00. The median estimate represents a +87.17% increase from the last price of 3.74.
The current consensus among 8 polled investment analysts is to Hold stock in AcelRx Pharmaceuticals Inc. This rating has held steady since March, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.